{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:19:44Z","timestamp":1781705984949,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-017-3967-0","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T10:09:11Z","timestamp":1515665351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study"],"prefix":"10.1186","volume":"18","author":[{"given":"Alexander R.","family":"Siebenh\u00fcner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhardt","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Feilchenfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Breitenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alain","family":"Clavien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Knuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Pestalozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"issue":"6","key":"3967_CR1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","volume":"37","author":"SA Khan","year":"2002","unstructured":"Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806\u201313.","journal-title":"J Hepatol"},{"issue":"5","key":"3967_CR2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594\u20139.","journal-title":"Oncologist"},{"issue":"6","key":"3967_CR3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268\u201389.","journal-title":"J Hepatol"},{"issue":"Suppl 6","key":"3967_CR4","first-page":"VI1","volume":"51","author":"SA Khan","year":"2002","unstructured":"Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Suppl 6):VI1\u20139.","journal-title":"Gut"},{"issue":"43","key":"3967_CR5","doi-asserted-by":"crossref","first-page":"12211","DOI":"10.3748\/wjg.v21.i43.12211","volume":"21","author":"Goetze TO","year":"2015","unstructured":"Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options. World J Gastroenterol. 2015;21(43):12211\u20137.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3967_CR6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000227373","volume":"51","author":"T Takada","year":"1994","unstructured":"Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994;51(5):396\u2013400.","journal-title":"Oncology"},{"issue":"2","key":"3967_CR7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147\u201356.","journal-title":"JAMA"},{"issue":"1","key":"3967_CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/SLA.0000000000001182","volume":"262","author":"J Kwon","year":"2015","unstructured":"Kwon J, Kim BH, Kim K, Chie EK, Ha SW. Survival benefit of adjuvant Chemoradiotherapy in patients with ampulla of Vater cancer: a systematic review and meta-analysis. Ann Surg. 2015;262(1):47\u201352.","journal-title":"Ann Surg"},{"issue":"16","key":"3967_CR9","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3967_CR10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/COC.0b013e31829e19fb","volume":"38","author":"MG McNamara","year":"2015","unstructured":"McNamara MG, Walter T, Horgan AM, et al. Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol. 2015;38(4):382\u20137.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"3967_CR11","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(6):2403\u201313.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"14","key":"3967_CR12","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381.","journal-title":"JAMA"},{"issue":"9","key":"3967_CR13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00001813-200010000-00006","volume":"11","author":"F Verderame","year":"2000","unstructured":"Verderame F, Mandina P, Abruzzo F, Scarpulla M, Di Leo R. Biliary tract cancer: our experience with gemcitabine treatment. Anti-Cancer Drugs. 2000;11(9):707\u20138.","journal-title":"Anti-Cancer Drugs"},{"issue":"39","key":"3967_CR14","first-page":"783","volume":"48","author":"S Kubicka","year":"2001","unstructured":"Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M, Phase II. Study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterology. 2001;48(39):783\u20139.","journal-title":"Hepato-Gastroenterology"},{"issue":"5","key":"3967_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000098109","volume":"70","author":"T Kiba","year":"2006","unstructured":"Kiba T, Nishimura T, Matsumoto S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006;70(5):358\u201365.","journal-title":"Oncology"},{"issue":"14","key":"3967_CR16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"7","key":"3967_CR17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00432-017-2392-8","volume":"143","author":"N Schweitzer","year":"2017","unstructured":"Schweitzer N, Weber T, Kirstein MM, et al. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. J Cancer Res Clin Oncol. 2017;143(7):1347\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3967_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00280-016-3206-4","volume":"79","author":"YS Kim","year":"2017","unstructured":"Kim YS, SY O, Go SI, et al. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. Cancer Chemother Pharmacol. 2017;79(1):99\u2013106.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"3967_CR19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.hpb.2016.07.008","volume":"18","author":"LL Dover","year":"2016","unstructured":"Dover LL, Oster RA, McDonald AM, DuBay DA, Wang TN, Jacob R. Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma. HPB (Oxford). 2016;18(10):843\u201350.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"3967_CR20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00595-016-1354-0","volume":"47","author":"T Mizuno","year":"2017","unstructured":"Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surg Today. 2017;47(2):182\u201392.","journal-title":"Surg Today"},{"issue":"8","key":"3967_CR21","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s11605-009-0900-0","volume":"13","author":"Y Murakami","year":"2009","unstructured":"Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg. 2009;13(8):1470\u20139.","journal-title":"J Gastrointest Surg"},{"issue":"suppl 5","key":"3967_CR22","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28\u201337.","journal-title":"Ann Oncol"},{"issue":"11","key":"3967_CR23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jhbp.283","volume":"22","author":"O Kainuma","year":"2015","unstructured":"Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepatobiliary Pancreat Sci. 2015;22(11):789\u201394.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"3967_CR24","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00280-014-2431-y","volume":"73","author":"M Toyoda","year":"2014","unstructured":"Toyoda M, Ajiki T, Fujiwara Y, et al. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemother Pharmacol. 2014;73(6):1295\u2013301.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"3967_CR25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/hpb.12413","volume":"17","author":"M Cho","year":"2015","unstructured":"Cho M, Wang-Gillam A, Myerson R, et al. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford). 2015;17(7):587\u201393.","journal-title":"HPB (Oxford)"},{"key":"3967_CR26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","volume":"15","author":"A Stein","year":"2015","unstructured":"Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564.","journal-title":"BMC Cancer"},{"issue":"7","key":"3967_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4251\/wjgo.v5.i7.171","volume":"5","author":"N Ramirez-Merino","year":"2013","unstructured":"Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: an update. World journal of gastrointestinal oncology. 2013;5(7):171\u20136.","journal-title":"World journal of gastrointestinal oncology"},{"key":"3967_CR28","doi-asserted-by":"crossref","unstructured":"Edeline J, Bonnetain F, Phelip J, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol. 2017;35(suppl 4S; abstr 225)","DOI":"10.1200\/JCO.2017.35.4_suppl.225"},{"key":"3967_CR29","doi-asserted-by":"crossref","unstructured":"BILCAP. A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. J Clin Oncol. 2011;29(suppl; abstr 4125):4125.","DOI":"10.1200\/jco.2011.29.15_suppl.4125"},{"key":"3967_CR30","doi-asserted-by":"crossref","unstructured":"Primrose J, Fox R, Palmer D, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol. 2017;35(suppl; abstr 4006):4006.","DOI":"10.1200\/JCO.2017.35.15_suppl.4006"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3967-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T03:47:24Z","timestamp":1570592844000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3967-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3967"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3967-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]},"article-number":"72"}}